Jupiter Neurosciences, Inc. Share Price & Technical Analysis
JUNS · $0.24 (-11.11%)
Healthcare / Biotechnology
$0.24
-11.11%
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinica…
Price chart
Seasonality
May has 1 positive and 1 negative years (last 3 years shown)
-50% return in May, 33% avg return in past 3 year May month.
-120% return in 2026, 59% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -50% | 0% | -20% | 0% | -50% | – | – | – | – | – | – | – | -120% |
| 25 | -91% | -30% | 0% | 0% | 33% | 25% | 40% | 7% | 20% | -22% | -14% | -17% | -49% |
| 24 | – | – | – | – | – | – | – | – | – | – | – | 168% | 168% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Weak
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements. The company researches and develops JNS115, which is in Phase IIa clinical trial for the treatment of Parkinson's disease; JNS108, which is in Phase II clinical trial for the treatment of mild cognitive impairment/early Alzheimer's disease; JNS102, which is in Phase II clinical trial for the treatment of mucopolysaccharidosis type 1; and JNS107, which is in Phase II clinical trial for the treatment of mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome. It is also involved in the commercialization and sale of GLO for skin beauty, MND for mental clarity, and PWR for energy, endurance, and muscle recovery under the Nugevia brand name. The company was formerly known as Jupiter Orphan Therapeutics, Inc. and changed its name to Jupiter Neurosciences, Inc. in August 2021. Jupiter Neurosciences, Inc. was incorporated in 2016 and is headquartered in Jupiter, Florida.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$13.04M
P/E ratio
—
52W high
$3.33
52W low
$0.17
Volume
84,45,655
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Jupiter Neurosciences, Inc. share price today?
- Jupiter Neurosciences, Inc. (JUNS) last traded around $0.24 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does JUNS have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for JUNS. Download the app for real-time alerts.
- How can I analyze Jupiter Neurosciences, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.